KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Operations: 2009-2024

Historic Cash from Operations for Sarepta Therapeutics (SRPT) over the last 16 years, with Dec 2024 value amounting to -$205.8 million.

  • Sarepta Therapeutics' Cash from Operations rose 79.37% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$244.6 million, marking a year-over-year increase of 30.60%. This contributed to the annual value of -$205.8 million for FY2024, which is 58.92% up from last year.
  • Sarepta Therapeutics' Cash from Operations amounted to -$205.8 million in FY2024, which was up 58.92% from -$501.0 million recorded in FY2023.
  • Over the past 5 years, Sarepta Therapeutics' Cash from Operations peaked at $107.5 million during FY2020, and registered a low of -$501.0 million during FY2023.
  • Over the past 3 years, Sarepta Therapeutics' median Cash from Operations value was -$325.3 million (recorded in 2022), while the average stood at -$344.0 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Cash from Operations spiked by 123.54% in 2020, and later slumped by 512.38% in 2021.
  • Yearly analysis of 5 years shows Sarepta Therapeutics' Cash from Operations stood at $107.5 million in 2020, then plummeted by 512.38% to -$443.2 million in 2021, then increased by 26.59% to -$325.3 million in 2022, then tumbled by 53.99% to -$501.0 million in 2023, then soared by 58.92% to -$205.8 million in 2024.